PMID- 33602156
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Feb 18
TI  - One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive 
      polypoidal choroidal vasculopathy patient.
PG  - 94
LID - 10.1186/s12886-021-01829-2 [doi]
LID - 94
AB  - BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is a type of age-related 
      macular degeneration that can cause permanent vision loss. The purpose of this 
      paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for 
      the treatment of PCV. METHODS: This was a prospective, single-arm, interventional 
      case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naive 
      patients. The patients were treated and monitored for 12 months. Each patient was 
      administered with an aflibercept (2.0 mg) injection every month for the first 3 
      months (the loading phase), and thereafter, once every 2 months. At every 
      follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, 
      and optical coherence tomography for measuring the central subfield macular 
      thickness (CSMT) were performed. Fluorescein and indocyanine green angiography 
      were conducted at baseline and at 4 and 12 months. RESULTS: After 12 months of 
      aflibercept therapy, the mean BCVA of the patients significantly improved from 
      65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly 
      decreased from 406.92 um at baseline to 276.12 um (p< 0.001). Additionally, ten 
      patients (40%) showed complete polyp regression. The treatment-naive patients 
      showed a statistically significant improvement in BCVA from 66.58 letters at 
      baseline to 76.36 letters at 12 months, and a significant decrease in CSMT, from 
      462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 
      letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically 
      significant. CONCLUSIONS: The fixed-dosing aflibercept regimen is effective for 
      treating patients with PCV and is more effective in treatment-naive patients than 
      in pre-treated patients. TRIAL REGISTRATION: Clinical Research Information 
      Service (CRiS), Republic of Korea. Identifer: KCT0005798, Registered: Jan 20, 
      2021. Retrospectively registered, URL: 
      https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18546.
FAU - Choo, Hun Gu
AU  - Choo HG
AD  - Department of Ophthalmology, Wonju College of Medicine - Yonsei University, 
      Wonju, Republic of Korea.
FAU - Lee, Jin Hae
AU  - Lee JH
AD  - Department of Ophthalmology, First St. Marys Eye Clinic, Seoul, Republic of 
      Korea.
FAU - Oh, Hyun Sub
AU  - Oh HS
AD  - Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro 
      Gangnam-gu, 06198, Seoul, Republic of Korea.
FAU - Kim, Soon Hyun
AU  - Kim SH
AD  - Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro 
      Gangnam-gu, 06198, Seoul, Republic of Korea.
FAU - You, Yong Sung
AU  - You YS
AD  - Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro 
      Gangnam-gu, 06198, Seoul, Republic of Korea.
FAU - Kwon, Oh Woong
AU  - Kwon OW
AUID- ORCID: 0000-0001-9786-6756
AD  - Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro 
      Gangnam-gu, 06198, Seoul, Republic of Korea. owkwon0301@yuhs.ac.
LA  - eng
PT  - Journal Article
DEP - 20210218
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Humans
MH  - Intravitreal Injections
MH  - Prospective Studies
MH  - *Receptors, Vascular Endothelial Growth Factor
MH  - Recombinant Fusion Proteins
MH  - Republic of Korea
MH  - *Tomography, Optical Coherence
MH  - Visual Acuity
PMC - PMC7890830
OTO - NOTNLM
OT  - Aflibercept
OT  - Age-related macular degeneration
OT  - Fixed-dosing regimen
OT  - Polypoidal choroidal vasculopathy
COIS- The authors declare that there is no conflict of interest.
EDAT- 2021/02/20 06:00
MHDA- 2021/05/15 06:00
PMCR- 2021/02/18
CRDT- 2021/02/19 05:40
PHST- 2020/07/31 00:00 [received]
PHST- 2021/01/21 00:00 [accepted]
PHST- 2021/02/19 05:40 [entrez]
PHST- 2021/02/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/02/18 00:00 [pmc-release]
AID - 10.1186/s12886-021-01829-2 [pii]
AID - 1829 [pii]
AID - 10.1186/s12886-021-01829-2 [doi]
PST - epublish
SO  - BMC Ophthalmol. 2021 Feb 18;21(1):94. doi: 10.1186/s12886-021-01829-2.